Brief: Nanorepro Says Paul Ehrlich Institute Evaluates Rapid COVID-19 Antigen Tests In Co's Portfolio
26/02/2021 14:59
Feb 26 (Reuters) - NANOREPRO AG NN6G.DE :
* RAPID COVID-19 ANTIGEN TESTS IN NANOREPRO AG'S PORTFOLIO
EVALUATED BY PAUL EHRLICH INSTITUTE
Source text for Eikon: ID:nEQ4DqJkha
Further company coverage: NN6G.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on NanoRepro AG
See all newsBrief: NanoRepro Enters Market For Diabetes Diagnostics
Brief: NanoRepro FY Profit After Taxes At EUR 29.7 Mln
Brief: Nanorepro Announces Talks With Viromed Group On Integration Of Individual Business Units Terminated For The Time Being
Brief: NanoRepro Completes Comparative Study, Says Its Tests Detect Omicron
Brief: NanoRepro - Change In Forecast 2021 And Outlook 2022 With Dividend